BELANTAMAB MAFODOTIN
UNII DB1041CXDG

Substance Identification & Data

This profile provides standardized clinical and technical data for Belantamab Mafodotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) DB1041CXDG.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2050232-20-5 and the RxNorm Concept ID (RxCUI) 2387834. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

DB1041CXDG

CAS Registry Number

2050232-20-5

RxNorm Concept ID

2387834

Detailed Substance Profile

Preferred Name

BELANTAMAB MAFODOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C114299

National Cancer Institute reference terminology for clinical and research data.

INN ID

10754

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

GH-35

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Belantamab Mafodotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

BELANTAMAB MAFODOTIN

BELANTAMAB MAFODOTIN-BLMF

Common Names & Synonyms

BELANTAMAB MAFODOTIN [INN]

BELANTAMAB MAFODOTIN [JAN]

BELANTAMAB MAFODOTIN [MI]

BELANTAMAB MAFODOTIN [USAN]

BELANTAMAB MAFODOTIN [WHO-DD]

BELANTAMAB MAFODOTIN BLMF [WHO-DD]

Brand / Trade Names

BLENREP

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY PROTEIN TNFRSF17),(HUMANIZED MONOCLONAL GSK2857914 .GAMMA.1-CHAIN), DISULFIDE WITH HUMANIZED MONOCLONAL GSK2857914 .KAPPA.-CHAIN, DIMER, TETRATHIOETHER WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)-N-METHYL-L-VALYL-L-VALYL-(3R,4S,5S)-3-METHOXY-5-METHYL-4-(METHYLAMINO)HEPTANOYL-(.ALPHA.R,.BETA.R,2S)-.BETA.-METHOXY-.ALPHA.-METHYL-2-PYRROLIDINEPROPANOYL-L-PHENYLALANINE

SYS

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 17 (B-CELL MATURATION PROTEIN, ANTIGEN CD269))HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN F.GAMMA.1 HEAVY CHAIN (1-451) (HUMANIZED VH (HOMO SAPIENS IGHV1-69*06 (84%) (IGHD)-IGHJ4*01 (86%)) (8.8.14) (1-121)-HOMO SAPIENS IGHG1*01 (122-451)) (224-214')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-214') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-33*01 (91%) IGKJ2*02 (6.3.9) (1'-107')-HOMO SAPIENS IGKC*01 (108'-214')), DIMER (230-230'':233-233'')-BISDISULFIDECONJUGATED, ON AN AVERAGE OF 4 CYSTEINYL RESIDUES (C), TO MONOMETHYL AURISTATIN F VIA MALEIMIDOCAPROYL LINKER.

SYS